Premium
Ponatinib‐induced neutrophilic panniculitis
Author(s) -
Zhang May,
Hassan Khaled M.,
Musiek Amy,
Rosman Ilana S.
Publication year - 2014
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.12326
Subject(s) - ponatinib , medicine , myeloid leukemia , panniculitis , tyrosine kinase inhibitor , leukemia , philadelphia chromosome , tyrosine kinase , pathology , dermatology , cancer research , nilotinib , imatinib , biology , cancer , receptor , chromosomal translocation , genetics , gene
Ponatinib is a bcr‐abl tyrosine‐kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome‐positive acute lymphoblastic leukemia that express bcr‐abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.